854633-21-9

Basic information

• Product Name: 5-bromo-2-methylbenzamide
• Synonyms: 5-bromo-2-methylbenzamide;IENXGTOPRPDOAE-UHFFFAOYSA-N
• CAS NO: 854633-21-9
• Molecular Formula: C₈H₈BrNO
• Molecular Weight: 214.05922
• Mol File: 854633-21-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-bromo-2-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-methylbenzamide(854633-21-9)
• EPA Substance Registry System: 5-bromo-2-methylbenzamide(854633-21-9)

Safety Data

• Hazardous Substances Data: 854633-21-9(Hazardous Substances Data)

Upstream product

• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 21900-41-4 5-bromo-2-methylbenzoyl?chloride 

Downstream Products

• 1393901-31-9 2-methyl-5-((trimethylsilyl)ethynyl)benzamide 
• 1266480-49-2 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzamide 
• 1393900-57-6 2-methyl-5-(2-(2-((4-(piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)benzamide 
• 1393901-34-2 tert-butyl 4-(4-((4-(3-carbamoyl-4-methylphenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1393901-33-1 tert-butyl 4-(4-((4-((3-carbamoyl-4-methylphenyl)ethynyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)piperazine-1-carboxylate 
• 1393901-32-0 5-ethynyl-2-methylbenzamide 

Relevant articles and documents

Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy

Nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) catalyzes the hydrolysis of extracellular nucleotides. It is expressed by immune cells and some carcinomas,e.g.of kidney and colon. Together with ecto-5′-nucleotidase (CD73), NPP3 produces immunosuppres

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

FAK AND FLT3 INHIBITORS

The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.

FAK INHIBITORS

A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.